US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

0.8700

-0.2800-24.35%

Post-market: 0.92230.0523+6.01%16:14 EDT

Volume:1.07M

Turnover:1.04M

Market Cap:2.95M

PE:-0.45

High:1.14

Open:1.09

Low:0.8480

Close:1.15

52wk High:9.59

52wk Low:0.8480

Shares:3.39M

Float Shares:2.25M

Volume Ratio:0.53

T/O Rate:47.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9469

EPS(LYR):-2.0691

ROE:-113.96%

ROA:-66.91%

PB:0.70

PE(LYR):-0.42

Loading ...

Overview Company News Filings

Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105

Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients

Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105

THOMSON REUTERS

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

THOMSON REUTERS

Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization

Kairos Pharma outlines mid-year oncology pipeline and funding plans

Kairos Pharma issues letter from CEO that recaps year, details plans for 2026

Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate

Kairos Pharma says shareholder letter now available to investors

Kairos Pharma Highlights Clinical Programs at LD Micro

Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)

Kairos Pharma Q1 net loss widens to $1.65 million; no revenue

Kairos Pharma announces annual shareholder meeting

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/KAPA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.87,"timestamp":1791403200000,"preClose":1.15,"halted":0,"volume":1069545,"hourTrading":{"tag":"盘后","latestPrice":0.9223,"preClose":0.87,"latestTime":"16:14 EDT","volume":176,"amount":161.03809919999998,"timestamp":1791404048294,"change":0.0523,"changeRate":0.060115,"amplitude":0.068966},"delay":0,"changeRate":-0.24347826086956517,"floatShares":2247529,"shares":3385400,"eps":-1.946945,"marketStatus":"Post-Mkt","change":-0.28,"latestTime":"10-07 16:23:41 EDT","open":1.09,"high":1.1399,"low":0.84795,"amount":1035078,"amplitude":0.25387,"askPrice":1,"askSize":100,"bidPrice":0.88,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.946945,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"listingDate":1717992000000,"exchange":"AMEX","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.09,"preClose":1.15,"latestTime":"09:24 EDT","volume":43501,"amount":46276.0288423,"timestamp":1791379494345,"change":-0.06,"changeRate":-0.052174,"amplitude":0.113043},"postHourTrading":{"tag":"盘后","latestPrice":0.9223,"preClose":0.87,"latestTime":"16:14 EDT","volume":176,"amount":161.03809919999998,"timestamp":1791404048294,"change":0.0523,"changeRate":0.060115,"amplitude":0.068966},"volumeRatio":0.52591},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":2247529,"roa":"-66.91%","roe":"-113.96%","lyrEps":-2.069102,"volumeRatio":0.52591,"shares":3385400,"dividePrice":0,"high":1.1399,"amplitude":0.25387,"preClose":1.15,"low":0.84795,"week52Low":0.84795,"pbRate":"0.70","week52High":9.59,"institutionHeld":0,"latestPrice":0.87,"committee":0.818182,"eps":-1.946945,"divideRate":0,"volume":1069545,"delay":0,"ttmEps":-1.946945,"open":1.09,"prevYearClose":4.97,"prevWeekClose":1.56,"prevMonthClose":1.64,"prevQuarterClose":1.64,"fiveDayClose":1.64,"twentyDayClose":1.66,"sixtyDayClose":2.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-01","symbol":"KAPA","defaultRemindTime":1788269400000,"type":"split","dateTimestamp":1788235200000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2026-10-06","current":-0.446854,"percent":1,"low":-25.607053,"twenty":-6.801812,"median":-3.619674,"eighty":-2.177991,"high":-0.90389,"avg":-4.443283,"sd":3.05052,"marketCap":5247081},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-18","current":-4.852143,"twenty":-8.578362,"median":-6.210138,"eighty":-4.078861,"marketCap":17186292},{"date":"2025-07-25","current":-4.424013,"twenty":-8.501541,"median":-6.156578,"eighty":-4.315248,"marketCap":15669854},{"date":"2025-08-01","current":-4.281779,"twenty":-8.456729,"median":-5.830571,"eighty":-4.144691,"marketCap":15166060},{"date":"2025-08-08","current":-4.566723,"twenty":-8.326712,"median":-5.698056,"eighty":-4.256377,"marketCap":16175333},{"date":"2025-08-15","current":-5.460044,"twenty":-8.265781,"median":-5.577408,"eighty":-4.144691,"marketCap":25722268},{"date":"2025-08-22","current":-5.151816,"twenty":-8.175816,"median":-5.56016,"eighty":-4.256377,"marketCap":24270205},{"date":"2025-08-29","current":-5.548109,"twenty":-8.117706,"median":-5.504045,"eighty":-4.350727,"marketCap":26137143},{"date":"2025-09-05","current":-6.825055,"twenty":-8.080211,"median":-5.554134,"eighty":-4.371339,"marketCap":32152835},{"date":"2025-09-12","current":-7.925871,"twenty":-8.146034,"median":-5.577408,"eighty":-4.403843,"marketCap":37338777},{"date":"2025-09-19","current":-5.90037,"twenty":-8.123413,"median":-5.684601,"eighty":-4.424013,"marketCap":27796645},{"date":"2025-09-26","current":-5.019718,"twenty":-8.080211,"median":-5.577408,"eighty":-4.452555,"marketCap":23647892},{"date":"2025-10-03","current":-5.063751,"twenty":-8.031527,"median":-5.554134,"eighty":-4.485854,"marketCap":23855329},{"date":"2025-10-10","current":-5.812305,"twenty":-7.985263,"median":-5.56016,"eighty":-4.525921,"marketCap":27381769},{"date":"2025-10-17","current":-5.151816,"twenty":-7.967725,"median":-5.531688,"eighty":-4.55855,"marketCap":24270205},{"date":"2025-10-24","current":-4.799555,"twenty":-7.967725,"median":-5.492822,"eighty":-4.58125,"marketCap":22610703},{"date":"2025-10-31","current":-5.019718,"twenty":-7.967725,"median":-5.46521,"eighty":-4.595432,"marketCap":23647892},{"date":"2025-11-07","current":-3.830837,"twenty":-7.967725,"median":-5.399832,"eighty":-4.525921,"marketCap":18047075},{"date":"2025-11-14","current":-3.48298,"twenty":-7.942613,"median":-5.371979,"eighty":-4.424013,"marketCap":16408318},{"date":"2025-11-21","current":-2.82458,"twenty":-7.922862,"median":-5.327946,"eighty":-4.230974,"marketCap":14298023},{"date":"2025-11-28","current":-3.42923,"twenty":-7.902108,"median":-5.296194,"eighty":-4.097795,"marketCap":17358761},{"date":"2025-12-05","current":-3.740193,"twenty":-7.855239,"median":-5.283914,"eighty":-3.903739,"marketCap":18932856},{"date":"2025-12-12","current":-3.331745,"twenty":-7.817744,"median":-5.203591,"eighty":-3.780288,"marketCap":16865295},{"date":"2025-12-19","current":-3.187781,"twenty":-7.79431,"median":-5.197038,"eighty":-3.655562,"marketCap":16136548},{"date":"2025-12-26","current":-3.052866,"twenty":-7.780249,"median":-5.190491,"eighty":-3.531486,"marketCap":15453608},{"date":"2026-01-02","current":-2.920419,"twenty":-7.780249,"median":-5.153702,"eighty":-3.48298,"marketCap":14783160},{"date":"2026-01-09","current":-3.989868,"twenty":-7.780249,"median":-5.151816,"eighty":-3.42923,"marketCap":20196712},{"date":"2026-01-16","current":-3.660807,"twenty":-7.780249,"median":-5.14469,"eighty":-3.42923,"marketCap":18531004},{"date":"2026-01-23","current":-3.208347,"twenty":-7.755842,"median":-5.119133,"eighty":-3.42923,"marketCap":16240655},{"date":"2026-01-30","current":-2.734499,"twenty":-7.661662,"median":-5.098261,"eighty":-3.381278,"marketCap":13842035},{"date":"2026-02-06","current":-2.426827,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"marketCap":12284598},{"date":"2026-02-13","current":-2.442869,"twenty":-7.51395,"median":-5.063751,"eighty":-3.27767,"marketCap":12365801},{"date":"2026-02-20","current":-2.303429,"twenty":-7.470914,"median":-5.048278,"eighty":-3.204892,"marketCap":11659957},{"date":"2026-02-27","current":-2.271757,"twenty":-7.452166,"median":-5.027001,"eighty":-3.156747,"marketCap":11499633},{"date":"2026-03-06","current":-2.698302,"twenty":-7.424045,"median":-5.019718,"eighty":-3.093003,"marketCap":13658807},{"date":"2026-03-13","current":-2.46796,"twenty":-7.400606,"median":-4.98699,"eighty":-3.049512,"marketCap":12492811},{"date":"2026-03-20","current":-2.529659,"twenty":-7.374048,"median":-4.948312,"eighty":-3.027281,"marketCap":12805132},{"date":"2026-03-27","current":-2.419423,"twenty":-7.358428,"median":-4.925987,"eighty":-2.995692,"marketCap":12247119},{"date":"2026-04-02","current":-2.380758,"twenty":-7.33968,"median":-4.899021,"eighty":-2.954226,"marketCap":12051399},{"date":"2026-04-10","current":-2.200475,"twenty":-7.311559,"median":-4.852143,"eighty":-2.923199,"marketCap":11985988},{"date":"2026-04-17","current":-2.403699,"twenty":-7.292811,"median":-4.845967,"eighty":-2.911648,"marketCap":13092947},{"date":"2026-04-24","current":-2.628935,"twenty":-7.263594,"median":-4.843588,"eighty":-2.858198,"marketCap":14319809},{"date":"2026-05-01","current":-2.220915,"twenty":-7.244298,"median":-4.831805,"eighty":-2.782532,"marketCap":12097326},{"date":"2026-05-08","current":-2.180035,"twenty":-7.217821,"median":-4.799555,"eighty":-2.739123,"marketCap":11874650},{"date":"2026-05-15","current":-1.805229,"twenty":-7.199074,"median":-4.787133,"eighty":-2.720186,"marketCap":10540732},{"date":"2026-05-22","current":-2.027078,"twenty":-7.170953,"median":-4.758877,"eighty":-2.696512,"marketCap":11836110},{"date":"2026-05-29","current":-1.932471,"twenty":-7.170953,"median":-4.74838,"eighty":-2.638077,"marketCap":11283701},{"date":"2026-06-05","current":-1.708789,"twenty":-7.161579,"median":-4.699647,"eighty":-2.62783,"marketCap":9977618},{"date":"2026-06-12","current":-1.680187,"twenty":-7.124084,"median":-4.685648,"eighty":-2.591975,"marketCap":9810610},{"date":"2026-06-18","current":-1.675786,"twenty":-7.124084,"median":-4.679404,"eighty":-2.58889,"marketCap":9784917},{"date":"2026-06-26","current":-1.374365,"twenty":-7.089251,"median":-4.661863,"eighty":-2.57116,"marketCap":8024917},{"date":"2026-07-02","current":-1.349796,"twenty":-7.079622,"median":-4.616471,"eighty":-2.529659,"marketCap":7881461},{"date":"2026-07-10","current":-1.356764,"twenty":-7.039719,"median":-4.598431,"eighty":-2.499514,"marketCap":7922143},{"date":"2026-07-17","current":-1.246389,"twenty":-7.030345,"median":-4.556506,"eighty":-2.476269,"marketCap":7277666},{"date":"2026-07-24","current":-1.092378,"twenty":-7.030345,"median":-4.471583,"eighty":-2.464669,"marketCap":6378395},{"date":"2026-07-31","current":-1.099712,"twenty":-7.030345,"median":-4.424013,"eighty":-2.432997,"marketCap":6421218},{"date":"2026-08-07","current":-1.430102,"twenty":-7.030345,"median":-4.370776,"eighty":-2.403935,"marketCap":8350367},{"date":"2026-08-14","current":-1.327826,"twenty":-6.98643,"median":-4.154767,"eighty":-2.384707,"marketCap":7708031},{"date":"2026-08-21","current":-1.204683,"twenty":-6.944825,"median":-4.098893,"eighty":-2.357708,"marketCap":6993186},{"date":"2026-08-28","current":-0.983831,"twenty":-6.936607,"median":-4.005778,"eighty":-2.333263,"marketCap":5711141},{"date":"2026-09-04","current":-0.973869,"twenty":-6.906926,"median":-3.91591,"eighty":-2.299446,"marketCap":5653307},{"date":"2026-09-11","current":-0.9797,"twenty":-6.869431,"median":-3.828893,"eighty":-2.28939,"marketCap":5687159},{"date":"2026-09-18","current":-1.05551,"twenty":-6.841837,"median":-3.754221,"eighty":-2.254791,"marketCap":6127237},{"date":"2026-09-25","current":-1.032184,"twenty":-6.834194,"median":-3.7005,"eighty":-2.216198,"marketCap":5991828},{"date":"2026-10-02","current":-0.909721,"twenty":-6.813433,"median":-3.652065,"eighty":-2.181371,"marketCap":5280933},{"date":"2026-10-06","current":-0.90389,"twenty":-6.801812,"median":-3.619674,"eighty":-2.177991,"marketCap":5247081}],"updateTime":1791404621607},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651463448","title":"Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463448?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118922,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in pa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","KAPA","MEDX","HYLG","BK4139","BBC","GDOC","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463982","title":"Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463982?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118907,"startTime":"0","endTime":"0","summary":"Kairos Pharma says Phase 1 ENV-105 plus Tagrisso trial shows no Grade 3+ toxicities in 13 patientsKairos Pharma reported interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in EGFR-mut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL9M2cfC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463351","title":"Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463351?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651146339","title":"Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2651146339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651146339?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648956752","title":"Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2648956752","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648956752?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:20","pubTimestamp":1782854405,"startTime":"0","endTime":"0","summary":"Kairos Pharma holds annual shareholder meeting, approves reverse stock split authorizationKairos Pharma held its 2026 annual shareholder meeting on June 29, 2026.Shareholders ratified Weinberg & Compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL3nYwkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570921","title":"Kairos Pharma outlines mid-year oncology pipeline and funding plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570921?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:37","pubTimestamp":1780576665,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On June 4, 2026, Kairos Pharma issued a mid-year update highlighting a term sheet to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640522157","title":"Kairos Pharma issues letter from CEO that recaps year, details plans for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640522157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640522157?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:18","pubTimestamp":1780575508,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157333","title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157333","media":"Reuters","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157333?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:15","pubTimestamp":1780575344,"startTime":"0","endTime":"0","summary":"Kairos Pharma signed a term sheet to acquire worldwide rights to CL-741 from privately held Celyn Therapeutics.CL-741 is an orally available, Phase 1-ready type IIb c-MET kinase inhibitor targeting EGFR-mutated NSCLC.Planned Phase 1 initiation in 2026; program also targets esophageal cancer, gastric cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL6xNyb8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294152","title":"Kairos Pharma says shareholder letter now available to investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294152?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:02","pubTimestamp":1780574538,"startTime":"0","endTime":"0","summary":"Kairos Pharma posted a mid-year 2026 letter to shareholders from CEO John Yu outlining priorities for the rest of the year.Letter highlights a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready oral type IIb c-MET inhibitor.Plan calls for initiating a Phase 1 CL-741 study in EGFR-mutated lung cancer; ENV-105 trials continue in prostate cancer, NSCLC results targeted by Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL39tg7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079453","title":"Kairos Pharma Highlights Clinical Programs at LD Micro","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079453","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079453?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110871,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an update. On May 18, 2026, Kairos Pharma, Ltd. released a new investor presentation and made it avail...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-highlights-clinical-programs-at-ld-micro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-highlights-clinical-programs-at-ld-micro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","LD","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635741674","title":"Analysts Offer Insights on Healthcare Companies: Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (IART) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635741674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635741674?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:50","pubTimestamp":1778773845,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kairos Pharma, Ltd. (KAPA), Integra Lifesciences (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kairos-pharma-ltd-kapa-integra-lifesciences-iart-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kairos-pharma-ltd-kapa-integra-lifesciences-iart-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IART","BK4532","LU0128526141.USD","BK4082","LABU","BK4139","BK4533","BK4581","LU0889565916.HKD","LU0320765992.SGD","KAPA","IE00B19Z9Z06.USD","BIIB","XLV","BK4137","LU0029874061.USD","IE00B894F039.SGD","LU0234570918.USD","LU0109394709.USD","XBI","IE00B19Z9P08.USD","BK4588","HCSG","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635633759","title":"Kairos Pharma Q1 net loss widens to $1.65 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635633759","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635633759?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:22","pubTimestamp":1778707323,"startTime":"0","endTime":"0","summary":"Kairos Pharma posted a net loss of $1.65 million for the quarter ended March 31, 2026, widening from $1.26 million a year earlier.Operating loss widened to $1.69 million as operating expenses climbed to $1.69 million from $1.27 million.Research and development spending rose to $684,000 from $493,000, while general and administrative costs increased to $1.01 million from $773,000.Company raised $385,000 in gross proceeds from an at-the-market offering, signed a manufacturing services agreement with Patheon committing $783,000, and expanded its Lonza work scope by about $2 million for ENV105 Phase II supply preparation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL5V2k1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0316494557.USD","LU1623119135.USD","LU0640476718.USD","LU2468319806.SGD","BK4548","LU0823416689.USD","LU2125910179.SGD","BK4581","IE00B19Z9505.USD","LU1815333072.USD","LU1989771016.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","LU0528227936.USD","LU2298321311.HKD","LU1791710400.SGD","LU2764263203.CNY","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2092937221.SGD","LU2764262908.HKD","TMO","LU0234572021.USD","IE0002141913.USD","LU2543165471.USD","KAPA","LU1548497426.USD","IE0009355771.USD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU2125909759.SGD","LU2357305700.SGD","IE00B2B36J28.USD","LU1923622291.USD","LU1670628061.USD","LU1854104046.USD","LU1923622614.USD","LU1720051108.HKD","LU1983299246.USD","BK4533","LU0320765489.SGD","LU2125910336.SGD","GB00BDT5M118.USD","LU2211814178.USD","LU1633808545.USD","LU2041044095.USD","LU2360108059.USD","LU0342679015.USD","LU1720051017.SGD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462535","title":"Kairos Pharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462535?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:30","pubTimestamp":1778272254,"startTime":"0","endTime":"0","summary":"Kairos Pharma scheduled Annual Meeting of Shareholders to be held virtually on June 29, 2026.Meeting materials expected to be finalized and filed with SEC ahead of distribution to shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL6nLCdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462371","title":"Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462371?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:30","pubTimestamp":1778272201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA3DQ6V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}]}}